NEWS HIGHLIGHTS
Published Studies Related to Novoseven (Coagulation Factor Viia)
Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients. [2010.12]
AIM: To investigate whether oseltamivir enhances the anticoagulant effect of warfarin and to evaluate any pharmacokinetic (PK) interaction between the agents... CONCLUSION: Concomitant administration of oseltamivir for 4.5 days to volunteers on daily warfarin had little or no effect on warfarin pharmacokinetics and no effect on pharmacodynamics. (c) 2010 The Authors. British Journal of Clinical Pharmacology (c) 2010 The British Pharmacological Society.
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. [2008.03]
BACKGROUND: We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment... CONCLUSIONS: Despite weight-adjusted dosing, female patients reached higher anti-Xa levels, suggesting increased sensitivity to dalteparin treatment. Healthy women and female patients also had higher coagulation activity, which might increase the risk of thrombus formation. The large proportion of patients with subtherapeutic anti-Xa during prolonged dalteparin treatment may reflect poor compliance and could thus contribute to the gradual loss of clinical efficacy.
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. [2005.05]
BACKGROUND: Activated recombinant coagulation factor VII (rFVIIa) effectively prevents and controls bleeding in patients with coagulopathy. Data show that rFVIIa may reduce blood loss and eliminate the need for transfusion in patients with normal haemostasis undergoing major surgery. We assessed the efficacy of rFVIIa in patients with normal haemostasis undergoing repair surgery of major traumatic fracture of the pelvis or the pelvis and acetabulum, who were expected to have a large volume of blood loss... CONCLUSIONS: In patients with normal haemostasis undergoing repair surgery of traumatic pelvic-acetabular fracture, the prophylactic use of rFVIIa does not decrease the volume of perioperative blood loss.
Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. [2005.02]
BACKGROUND: Prevention of bleeding episodes in noncirrhotic patients undergoing partial hepatectomy remains unsatisfactory in spite of improved surgical techniques. The authors conducted a randomized, placebo-controlled, double-blind trial to evaluate the hemostatic effect and safety of recombinant factor VIIa (rFVIIa) in major partial hepatectomy... CONCLUSIONS: Recombinant factor VIIa dosing did not result in a statistically significant reduction in either the number of patients transfused or the volume of blood products administered. No safety issues were identified.
Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. [2004.07]
To establish the pharmacokinetic profile of activated recombinant coagulation factor VII (rFVIIa; NovoSeven in children with haemophilia A, and to compare it with the pharmacokinetic profile in adults with haemophilia A. Twelve children (2-12 years) received one single dose of rFVIIa 90 and 180 micrograms kg(-1) in randomized order separated by a washout period of 48 h to 1 month...
Clinical Trials Related to Novoseven (Coagulation Factor Viia)
The FEIBA NovoSeven Comparative Study [Completed]
FENOC is a prospective, open-label, randomized, cross-over, multi-center study to
investigate and compare the hemostatic effect and cost-efficacy of two different by-passing
agents in the treatment of joint hemorrhages in subjects with severe hemophilia A and
inhibitors. The study is designed as a clinical equivalency trial.
A Study to Evaluate Safety and Efficacy of NovoSeven� in Patients With Glanzmann's Thrombasthenia in Japan [Enrolling by invitation]
This study is conducted in Asia. The aim of the study is to evaluate the safety and efficacy
of NovoSeven® (activated recombinant factor VII, eptacog alfa (activated)) during bleeding
episodes and for the prevention of bleeding during surgery/delivery in patients with
Glanzmann's thrombasthenia (GT)/Glanzmann's disease.
Post-marketing Safety Surveillance of NovoSeven� in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database [Completed]
This study is conducted in Europe. The purpose of this retrospective study is to collect
additional safety information of patients with haemophilia and inhibitors who are treated
with rFVIIa.
A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor [Completed]
Activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII
(rFVIIa) are the only two drugs that are available to treat bleeds in haemophilia A patients
with high titer inhibitors. However, management of bleeds in these patients can be
challenging due to variation in response and lack of standardized methods to monitor the
effect. We hypothesized that significant increase in whole blood clot stability could be
achieved when tranexamic acid was given concomitantly with bypassing-agents while thrombin
generation remains unaffected. In this prospective crossover study the effect of aPCC and
rFVIIa with and without TXA on clot stability and thrombin generation capacity (ETP) were
studied, using thromboelastography (ROTEM) and thrombin generation assay (TGA),
respectively. In addition, the risk of thrombosis and disseminated intravascular coagulation
(DIC) was assessed.
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors [Completed]
This trial is conducted in Europe. The aim of the trial is to investigate the
pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the
effect of the investigated drug on the body) of rFVIIa (activated coagulation factor VII)
following one single injection of 270 microg/kg compared to three injections of 90 microg/kg
rFVIIa in patients with haemophilia.
Reports of Suspected Novoseven (Coagulation Factor Viia) Side Effects
Haemorrhage (8),
Death (8),
Deep Vein Thrombosis (8),
Troponin I Increased (6),
Multi-Organ Failure (5),
Cerebral Infarction (5),
Abdominal Pain (4),
Drug Ineffective (4),
Disseminated Intravascular Coagulation (3),
Device Related Infection (3), more >>
|
